Abstract
Eribulin mesylate, a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits cancer cell proliferation at low-nanomolar levels. In a multicenter ECOG trial, patients with progressive metastatic CRPC, ECOG 0-2 were treated with eribulin 1.4 mg/m as an IV bolus over 5 minutes on days 1 and 8 of a 21-day cycle. This noncomparative study stratified points to either a chemonaive (CN), prior-taxane (Tax) only, or 2 prior cytotoxic (TCx) chemotherapy arm. The trial was powered to detect a 50% PSA reduction using Consensus Criteria in at least 40% versus 20% (90% power, one-sided α=0.10) for the CN stratum and 25% versus. 10% (power 87%, one-sided α=0.10) for the Tax and TCx strata. In total, 119 pts received treatment of which 116 were eligible for the primary response determination in this study. Median age 70 years (range, 45 to 88); median number of treatment cycles 4 (range, 1 to 20+); ECOG 0-1 90%. Confirmed PSA response rates (50% decline from baseline) were 29% (90% [18.2%, 41.2%]; P=0.20), 10% (90% [5.2%, 27.1%]; P=1.00), and 4% ([0.2%, 18.3%]; P=0.59) in the chemonaive stratum, the prior-taxane stratum, and the 2-prior-chemotherapy stratum, respectively. Median progression-free survival was 3.5 mont...Continue Reading
References
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BubleyG Wilding
Feb 3, 2000·Journal of the National Cancer Institute·P TherasseS G Gwyther
Aug 18, 2004·Cancer Research·Galina KuznetsovBruce A Littlefield
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Jul 16, 2005·Molecular Cancer Therapeutics·Mary Ann JordanLeslie Wilson
Dec 25, 2009·Biochemistry·Jennifer A SmithMary Ann Jordan
Sep 3, 2010·Cancer Research·Meng-Lei ZhuNatasha Kyprianou
Oct 5, 2010·Lancet·Johann Sebastian de BonoUNKNOWN TROPIC Investigators
Mar 8, 2011·Lancet·Javier CortesUNKNOWN EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators
Jul 30, 2011·Cancer Research·Medha S DarshanParaskevi Giannakakou
Sep 10, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J S de BonoD P Petrylak
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Feb 22, 2014·Cancer Research·Maria Thadani-MuleroParaskevi Giannakakou
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Apr 4, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicholas F Dybdal-HargreavesSusan L Mooberry
Jul 17, 2015·JAMA Oncology·Emmanuel S AntonarakisJun Luo
Aug 6, 2015·The New England Journal of Medicine·Christopher J SweeneyRobert S DiPaola
Jan 1, 2016·Lancet·Nicholas D JamesUNKNOWN STAMPEDE investigators
Feb 15, 2016·Lancet·Patrick SchöffskiShreyaskumar R Patel
Jun 6, 2017·The New England Journal of Medicine·Karim FizaziUNKNOWN LATITUDE Investigators
Jun 6, 2017·The New England Journal of Medicine·Nicholas D JamesUNKNOWN STAMPEDE Investigators
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
May 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J S de BonoD P Petrylak